PUBLIC-CONTRACT SUPPLIER PROFILE
Companies House OC392078 · Active. Observed evidence is kept separate from ownership, risk and renewal inferences.
Names are retained exactly as published and are not treated as separate legal entities.
Every relationship carries its source, date and match method. Exact identifier edges are observed; name-derived ownership or group paths remain inferred.
BLAKE MORGAN LLP
Exact GB-COH company number published on a Contracts Finder supplier record and resolved to the same register number.
The exact identity projection does not contain a publishable parent edge for this supplier. Absence is not evidence of independence.
Checked exact Companies House identity, held LEI identity where present and the Who Owns This Brand name candidate; no exact parent edge returned.
The held funding directory did not return a verified exact-company match. That does not prove the company has never raised capital.
These inputs help prioritise research; they do not rate supplier quality, solvency, integrity or future award prospects.
Registry status is an observed field, not a performance or solvency conclusion.
Exact Companies House number OC392078.
BLAKE MORGAN LLP · incorporated 21/03/2014. The R2 record excludes officers, PSCs, addresses and contact data.
Exact Companies House number OC392078 resolved through the approved 5.7-million-record R2 projection.
Verify the current deadline on the live register before relying on this projected date.
Accounts due field from the dated Companies House projection for OC392078.
2 fall within 12 months. End dates do not prove a reprocurement or renewal.
Exact supplier company number OC392078; date window applied to published contract_end fields.
General Pharmaceutical Council appears on 1 of 3 linked notices. This is notice concentration, not revenue dependency.
Derived share = leading buyer notice count ÷ all exact-company-linked notices; values and contract delivery are not used.
A published end date is used only to prioritise source checks. It does not predict buyer intent, supplier retention or a future tender.
Derived from published contract end dates within 12 and 24 months of the current date.
No supplier risk score: Observed records and inferred review signals are never combined into a supplier risk score. Missing evidence is not a clean bill of health, proof of independence or proof that no funding or ownership relationship exists.
These are award-notice delivery fields, not headquarters, workforce location or measured local economic impact. ONS population is neutral regional context.
Exact supplier company number OC392078; grouped by the delivery region published on each award notice. This is not supplier-headquarters geography.
ONS Census population for West Midlands (E12000005); context only, not attributed economic impact.
Exact supplier company number OC392078; grouped by the delivery region published on each award notice. This is not supplier-headquarters geography.
ONS Census population for London (E12000007); context only, not attributed economic impact.
Exact supplier company number OC392078; grouped by the delivery region published on each award notice. This is not supplier-headquarters geography.
Showing 2 of 2 records ending within 24 months. This is a research queue, not a renewal forecast.
General Pharmaceutical Council
Exact supplier company number OC392078; contract end date copied from the published award notice.
Department for Education
Exact supplier company number OC392078; contract end date copied from the published award notice.
Open the permanent evidence page, then verify material facts at the official source.
Notice values may be framework ceilings, amendments or multi-supplier totals. They are not verified revenue, payment, delivery quality, profitability or proof of wrongdoing.